Page 2 - Tuft School News Today

1 post published by lobotero on April 22, 2023

Happy Earth Day....hug a tree today. The weekend begins and the world continues to turn....and it is up to me to give you all the news that was unfit for public consumption. New sports are popping up everywhere....frizbee football, cornholing, teqball, and then there is pickleball. Pickleball has gained popularity so much so that courts…

TUESDAY, April 18, 2023 (HealthDay News) -- Most cases of type 2 diabetes can be linked to making poor food choices, a new study finds.

Most cases of Type 2 diabetes can be linked to making poor food choices, a new study finds.

The CDC expects to see a 700% increase in the number of young Americans diagnosed with Type 2 diabetes by 2060. It's both a national and global problem and, according to...

Down on energy efficiency and conservation. on renewables, we have a long term strategy we can use. frankly, i have a hard time not seeing what opec has done as a direct response to what we have done in this congress to give people access to cleaner, and cheaper energy. because, nothing scares the oil company like a bunch of people with solar panels and electric vehicles. >> you are right about that. i want to have you back to have that specific conversation about the fact that it is actually th...

A new study by researchers at the University of Oxford and Tufts University suggests that the onset of Alzheimer’s disease may be triggered by the activation of two common viruses.

Alzheimer's disease can begin almost imperceptibly, often masquerading in the early months or years as forgetfulness that is common in older age. What causes the disease remains largely a mystery.

Varicella zoster virus (VZV), the virus that causes chickenpox and shingles, may activate the herpes simplex virus and trigger the onset of Alzheimer's disease, a new mouse study found.

An initial $6.7 million grant comes from the National Institute on Drug Abuse, part of the National Institutes of Health. Copernicus, a clinical-stage gene therapy company in Cleveland, and Northeastern, which is in Boston, said the grant has the potential for an additional $8 million in Phase 2 funding 'to further move the gene therapy toward clinical trials.'